Related references
Note: Only part of the references are listed.Matrix Metalloproteinase-9 Is Associated with Relapse and Prognosis of Patients with Colorectal Cancer
Dake Chu et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients
A. M. J. Langers et al.
BRITISH JOURNAL OF CANCER (2012)
Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features
Yi Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer
Pavlos Lampropoulos et al.
TUMOR BIOLOGY (2012)
Molecular Genetics of Colorectal Cancer
Eric R. Fearon
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
MMP-7 as a prognostic marker in colorectal cancer
Selja Koskensalo et al.
TUMOR BIOLOGY (2011)
MMP-9 (Gelatinase B) Expression is Associated With Disease-Free Survival and Disease-Specific Survival in Colorectal Cancer Patients
Riyad Bendardaf et al.
CANCER INVESTIGATION (2010)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells - Associations with histopathology and patients outcome
Soren Astrup Jensen et al.
EUROPEAN JOURNAL OF CANCER (2010)
Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer
Yongning Zhou et al.
TUMOR BIOLOGY (2010)
Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer
Yu-Jing Fang et al.
TUMOR BIOLOGY (2010)
Matrix metalloproteinase proteomics: substrates, targets, and therapy
Charlotte J. Morrison et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy
Diclehan Unsal et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not
A. M. J. Langers et al.
BRITISH JOURNAL OF CANCER (2008)
Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer
Yong Beom Cho et al.
HUMAN PATHOLOGY (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Matrix metalloproteinases and the regulation of tissue remodelling
Andrea Page-McCaw et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
G. Des Guetz et al.
BRITISH JOURNAL OF CANCER (2006)
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer
Y Ogata et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer
T Takeuchi et al.
CLINICAL CANCER RESEARCH (2004)
Matrix metalloproteinases as modulators of inflammation and innate immunity
WC Parks et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Regulation of matrix biology by matrix metalloproteinases
JD Mott et al.
CURRENT OPINION IN CELL BIOLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
